Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
* * $AMRX Video Chart 05-11-2020 * *
Link to Video - click here to watch the technical chart video
$182 price target from 2 analysts is not unreasonable for AMRX Amneal.
U.S. Pharma company is EXTREMELY Valuable right now. NOW more than ever before U.S.Pharma will Thrive!!$$$$$
Please help me understand why and how they derived a $182 price target...yet the current $4 price is so far off from their estimates. Thank you
HUGE BEAT for AMRX!!!
Monday is going to be a Big day for AMRX $$$$
500K Buy eod today.
EXTREMELY BULLISH SIGN! $$$$
AMRX
Pay Attn.
Less than 1 year ago... JP Morgan AND Raymond James both put AMRX price target at $182.
Its now $3.55.
But not for long.
is everyone watching AMRX?!
RATED EXTREME BUY!$$$
AMRX
Amneal Launches Generic Butrans® Following ANDA Approval by FDA
Business Wire
April 16, 2020, 7:00 am
Awesome day for AMRX today. Much Better days coming. $$$$
AMRX $3.30 is going to make a lot of people very rich if you ask my opinion!!$$$
Governor Ron DeSantis Fl, Announced on Tuesday 4/9/20.
Another big manufacturer, Teva, is in this arena. I hope this drug works perfectly for everyone.
https://apple.news/AtIDx7umySlCOIMR73fEEqA
I wonder how this news will affect our share price with so many other manufacturers making this same drug as well.
https://www.foxbusiness.com/lifestyle/india-to-ship-potential-coronavirus-drug-sought-by-trump
Giving 400000 to New Orleans to help. Supplying all the areas that are the centers of covid19 issues. Just bought some as we will need a lot due to fda approval of this treatment.
yep common sense, even if you didn't know that it's common sense not to take fish tank cleaner
chloroquine is a fish tank cleaner NOT hdrochlorquine. Couple used chloroquine, husband died, wife in intensive care!
AMRX hydroxychloroquine 20 million tablets being produced....$$$
$AMRX
https://nypost.com/2020/03/23/ny-will-turn-to-experimental-drugs-for-worst-coronavirus-cases-cuomo/
New York plans to start administering a pair of untested treatments to seriously ill coronavirus patients on a “compassionate care” basis, Gov. Cuomo said Monday.
“On the drug therapy, Tuesday we’re going to start the hydroxychloroquine with these Zithromax, that’s the drug combination that the president has been talking about,” Cuomo said during a news conference in Albany.
Cuomo said the Food and Drug Administration had also given the state permission to “proceed with an experimental drug” that “takes the plasma from a person who has been infected with the virus, processes the plasma and injects the antibodies into a person who is sick.”
“And there have been tests that show when a person is injected with the antibodies that then stimulates and promotes the immune system against that disease,” he said.
“We all believe thousands and thousands of people have had the virus and self resolved,” he said.
Cuomo also said experts in New York were developing “a serological drug, where you Cuomo also said experts in New York were developing “a serological drug, where you
test the antibodies of a person and see if they have the virus already.”
“If you knew that, you would know who is now immune to the virus and who you could send back to work, etc., so we’re also working on that.”
President Trump tweeted Saturday that the combination of hydroxychloroquine — an anti-malaria drug sold under the brand name Plaquenil — and Zithromax, the brand name for the antibiotic azithromycin, could be “one of the biggest game-changers in the history of medicine.”
Results of a small French study published last week showed that five of six people with the coronavirus who were treated with the two-drug cocktail tested negative on Day Three, and all tested negative on Day Six.
Dr. Anthony Fauci, director of the National Institute of Allergy and Infection Diseases, cautioned Saturday that the combination of drugs hadn’t been proven to work in clinical trials.
“It’s only a trial, it’s a trial for people who are in serious condition, but the New York State Department of Health has been working on this with some of New York’s best health care agencies and we think it shows promise and we’re going to be starting that this week.”
AMRX Covid 19 Friday AH news:AMRX news: Amneal Accelerates Distribution and Production of Hydroxychloroquine Sulfate to Meet Potential Needs of COVID-19 Patients Nationwide
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”), one of the largest U.S.-based generics manufacturers, today announced that it is responding to the national COVID-19 health emergency by building on its existing supply of hydroxychloroquine sulfate.
Amneal is ramping up production of hydroxychloroquine sulfate at several of its manufacturing sites and expects to produce approximately 20 million tablets between now and mid-April. Those tablets will be made available nationwide through Amneal’s existing retail and wholesale customers, as well as through direct sales to larger institutions in need.
“This is a critical time in the fight against COVID-19,” said Chirag and Chintu Patel, Co-Chief Executive Officers. “With our existing supply of hydroxychloroquine sulfate, and the ability to fast-track production, Amneal is well-positioned to help meet the potential demand for patients in need. We are grateful to our employees for working to accelerate production and will continue to do everything we can to support the healthcare needs of our communities.”
Hydroxychloroquine sulfate was first synthesized in 1946 and is in a class of medications historically used to treat and prevent malaria. Today, Amneal’s hydroxychloroquine sulfate tablets are approved by the U.S. Food and Drug Administration (FDA) to treat malaria, rheumatoid arthritis, lupus, childhood arthritis and other autoimmune diseases. Hydroxychloroquine is not approved for the treatment of COVID-19; however, it has been identified as a possible treatment for COVID-19,1 and the U.S. government has requested its immediate availability.
Amneal has already begun shipping product. As a socially responsible company, Amneal will work to ensure its available inventory allocation is widely and evenly distributed to benefit the most patients possible.
About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has manufacturing operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.
Amneal has an extensive portfolio of more than 225 marketed commercial products and is expanding its portfolio to include complex dosage forms, including biosimilars, in a broad range of therapeutic areas. The Company also markets a portfolio of branded pharmaceutical products through its Specialty segment focused principally on central nervous system and endocrine disorders. For more information, visit https://www.amneal.com.
Forward-Looking Statements
Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995, as amended). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, including, among other things, future operating results and financial performance, product development and launches, integration strategies and resulting cost reduction, market position and business strategy. Words such as “may,” “will,” “could,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “assume,” “continue,” and similar words are intended to identify estimates and forward-looking statements.
The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Amneal. A list and descriptions of these risks, uncertainties and other factors can be found in the Company’s most recently filed Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as supplemented by any subsequently filed Quarterly Reports on Form 10-Q. Copies of these filings are available online at www.sec.gov, www.amneal.com or on request from the Company.
Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof, except as otherwise required by United States securities laws.
1 https://www.who.int/blueprint/priority-diseases/key-action/Table_of_therapeutics_Appendix_17022020.pdf?ua=1
PP-PRS--US-0003
https://cts.businesswire.com/ct/CT?id=bwnews&sty=20200320005551r1&sid=acqr8&distro=nx&lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20200320005551/en/
Tim Lynch / Jamie Moser
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449
Source: Amneal Pharmaceuticals, Inc.
© Copyright Business Wire 2020
$AMRX
AMNEAL and AvKare ALSO LIST Zmax for Corvid19 treatment
Has a generic version of Zithromax been approved?
Yes. The following products are equivalent to Zithromax:
(Manufacturer: PFIZER)
azithromycin for suspension;oral
Manufacturer: AMNEAL PHARMS LLC (AMRX)
Approval date: July 19, 2018
Strength(s): EQ 100MG BASE/5ML [AB], EQ 200MG BASE/5ML [AB]
This says Amneal can manufacture this drug.
(I do not find it listed on there site at present but it is listed at AvKare.)
https://www.drugs.com/availability/generic-zithromax.html
AvKare on its products page lists it below PIC.
IMHO it should give easier access for DOD, VA and U.S. federal
agency sectors through (AMRX) Avkare distribution channels.
(AMRX)
Amneal Just Acquired 65% OF AvKARE 1/31/20 DOD, VA, Leader in Federal Markets
AvKARE is one of the largest private label providers of generic pharmaceuticals in the U.S. federal agency sector, primarily focused on serving the Department of Defense (“DoD”) and the Department of Veterans Affairs (“VA”). The company utilizes its relationships with more than 50 generic pharmaceutical vendors to offer a proprietary line of specially packaged products under its own labels.
We have launched 15 new generic products, including high-value first-to-market ones like NuvaRing and Carafate, have one new award for our base business, we have seen continued script growth for key specialty products Rytary and Unithroid, we have already increased our generics gross margin by 350 basis points from Q3 to Q4 2019 and continue to make progress. We have entered into a collaboration with Fosun Pharma to enter the Chinese market with certain products from our product portfolio. And we have executed on the acquisition of a majority stake in AvKARE, which diversifies our channel mix and provides an attractive durable revenue stream. As you can see our efforts are already bearing fruit. Our fourth quarter results build on the momentum from the third quarter and demonstrate that our strategies are working and these result sets up nicely to enter 2020 with strong momentum.
AvKARE has already won 34 national contracts and we expect that number to grow.
As we look ahead to our full year 2020 financial outlook, we previously expressed our expectation that 2020 would be a growth year for Amneal. That is still our expectation. We also closed the AvKARE transaction at the end of January and the expected contribution from that business for the balance of the year is reflected in our outlook.
In terms of the numbers, we expect annual revenues of between $1.88 billion and $1.98 billion, driven primarily by growth in our generic segment and the additional revenues from AvKARE. We expect adjusted gross margin between 44% and 46%, EBITDA in the range of $400 million to $450 million and adjusted diluted earnings per share of $0.45 per share to $0.60 per share based on weighted average diluted shares outstanding of approximately 300 million shares.
This info taken from february (AMRX) Q4 2019 Earnings Call Transcript..
fool.com/earnings/call-transcripts/2020/02/26/amneal-pharmaceuticals-inc-amrx-q4-2019-earnings-c.aspx
yep shot a bit after close on production ramping up
$AMRX lowest float of 3 Hydroxychloroquine stocks..others are $MY~ $TEV~
AMRX news: Amneal Accelerates Distribution and Production of Hydroxychloroquine Sulfate to Meet Potential Needs of COVID-19 Patients Nationwide
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”), one of the largest U.S.-based generics manufacturers, today announced that it is responding to the national COVID-19 health emergency by building on its existing supply of hydroxychloroquine sulfate.
Amneal is ramping up production of hydroxychloroquine sulfate at several of its manufacturing sites and expects to produce approximately 20 million tablets between now and mid-April. Those tablets will be made available nationwide through Amneal’s existing retail and wholesale customers, as well as through direct sales to larger institutions in need.
“This is a critical time in the fight against COVID-19,” said Chirag and Chintu Patel, Co-Chief Executive Officers. “With our existing supply of hydroxychloroquine sulfate, and the ability to fast-track production, Amneal is well-positioned to help meet the potential demand for patients in need. We are grateful to our employees for working to accelerate production and will continue to do everything we can to support the healthcare needs of our communities.”
Hydroxychloroquine sulfate was first synthesized in 1946 and is in a class of medications historically used to treat and prevent malaria. Today, Amneal’s hydroxychloroquine sulfate tablets are approved by the U.S. Food and Drug Administration (FDA) to treat malaria, rheumatoid arthritis, lupus, childhood arthritis and other autoimmune diseases. Hydroxychloroquine is not approved for the treatment of COVID-19; however, it has been identified as a possible treatment for COVID-19,1 and the U.S. government has requested its immediate availability.
Amneal has already begun shipping product. As a socially responsible company, Amneal will work to ensure its available inventory allocation is widely and evenly distributed to benefit the most patients possible.
About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has manufacturing operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.
Amneal has an extensive portfolio of more than 225 marketed commercial products and is expanding its portfolio to include complex dosage forms, including biosimilars, in a broad range of therapeutic areas. The Company also markets a portfolio of branded pharmaceutical products through its Specialty segment focused principally on central nervous system and endocrine disorders. For more information, visit https://www.amneal.com.
Forward-Looking Statements
Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995, as amended). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, including, among other things, future operating results and financial performance, product development and launches, integration strategies and resulting cost reduction, market position and business strategy. Words such as “may,” “will,” “could,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “assume,” “continue,” and similar words are intended to identify estimates and forward-looking statements.
The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Amneal. A list and descriptions of these risks, uncertainties and other factors can be found in the Company’s most recently filed Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as supplemented by any subsequently filed Quarterly Reports on Form 10-Q. Copies of these filings are available online at www.sec.gov, www.amneal.com or on request from the Company.
Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof, except as otherwise required by United States securities laws.
1 https://www.who.int/blueprint/priority-diseases/key-action/Table_of_therapeutics_Appendix_17022020.pdf?ua=1
PP-PRS--US-0003
https://cts.businesswire.com/ct/CT?id=bwnews&sty=20200320005551r1&sid=acqr8&distro=nx&lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20200320005551/en/
Tim Lynch / Jamie Moser
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449
Source: Amneal Pharmaceuticals, Inc.
© Copyright Business Wire 2020
$AMRX
What Is Hydroxychloroquine? Donald Trump Says Malaria Drug for Coronavirus Has Been Approved by FDA
BY ARISTOS GEORGIOU ON 3/19/20 AT 12:50 PM EDT
President Donald Trump announced Thursday that the Food and Drug Administration (FDA) has approved hydroxychloroquine—a drug used to treat malaria, rheumatic diseases and other conditions—for COVID-19.
As the COVID-19 pandemic spreads around the world, scientists are scrambling to identify treatments that may be effective against the disease. Hydroxychloroquine—a common derivative of chloroquine—is among those touted as most promising by some experts.
"The nice part is, it's been around for a long time, so we know that if things don't go as planned its not going to kill anybody," Trump told reporters at a press conference. "When you go with a brand new drug, you don't know if that's going to happen. Its shown very very encouraging early results and we're going to be able to make that drug available almost immediately."
But how effective is the drug? This week, researcher Didier Raoult from Aix-Marseille University in France, one of the main proponents for using hydroxychloroquine to treat infection with the novel coronavirus—known as SARS-CoV-2—released encouraging results of a preliminary trial involving a total of 36 COVID-19 patients.
According to a draft paper—which has not yet been accepted for publication in a peer-reviewed scientific journal—six of these patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight had lower respiratory tract infection symptoms.
Between early and mid-March, Raoult and his team treated 20 of these patients with 600 milligrams of hydroxychloroquine daily in a hospital setting. Depending on their symptoms, an antibiotic known as azithromycin was also added to the treatments. This antibiotic is known to be effective against complications from bacterial lung disease. The 16 remaining patients were not given the drug as a control.
In the study, the scientists observed a "significant" reduction in viral load in the patients treated with hydroxychloroquine, and that the effect was reinforced by azithromycin, Medscape reported.
In fact, after six days, 70 percent of the treated patients were considered cured, meaning that the virus was no longer detected in samples taken from them, compared to 12.5 percent of the control group patients. Furthermore, all six patients who were treated with both hydroxychloroquine and the antibiotic azithromycin tested negative for the virus after six days.
While encouraging, it is important to note that this is an unpublished preliminary study, so the results should be viewed with caution. The sample size is small, and the study was non-randomized, meaning people were allocated to different interventions using non-random methods. The study was also "unblinded," meaning that all parties—i.e. the medical staff, patients and researchers—were aware of the treatments the participants received.
Randomization and blinding—where one or more parties are kept unaware of which treatments patients received—are used to prevent conscious or unconscious bias from affecting the results of the trial. Nevertheless, Raoult and colleagues decided to publicly release their early results due to the unprecedented nature of the COVID-19 outbreak. "For ethical reasons and because our first results are so significant and evident we decide to share our findings with the medical community, given the urgent need for an effective drug against SARS-CoV-2 in the current pandemic context," the authors wrote in the draft paper.
Some experts—such as Andrew Preston from the University of Bath in the U.K.—stress that larger, controlled trials need to be conducted to truly determine the effectiveness of hydroxychloroquine as a treatment for COVID-19. "Remarkably, this study finished on March 16, but the group have released their results publicly in the hope of stimulating other studies to establish larger data sets," Preston said in a statement provided Science Media Centre U.K. "This rapid and open release of data is typical of the response to the COVID-19 pandemic, and recognizes the urgent and desperate need for any tool that might help treat patients and stem the tide of infection."
"The results have yet to be fully scrutinized, and of course, it is essential to conduct other, larger controlled trials to determine accurately the effectiveness of [the drug] as a treatment for COVID-19. But in among the oppressive darkness of the current situation, any glimmer of hope is very welcome."
Raoult's study—the first to test hydroxychloroquine on patients—follows some promising research from China. One preliminary trial involving 100 patients indicated that chloroquine was effective in the treatment of COVID-19-related pneumonia, without the presence of severe side effects, according to a paper published in the journal BioScience Trends.
Other in vitro research—tests conducted using cells in test tubes rather than inside patients—also indicated the potential efficacy of chloroquine.
According to Raoult, the effect of both chloroquine and its derivative hydroxychloroquine is probably the same since the mechanism of action of these two closely-related molecules is identical, he noted in a study published in the International Journal of Antimicrobial Agents. For around a decade, studies have reported potential anti-viral properties of these two substances against flu and SARS—another form of coronavirus.
With regards to hydroxychloroquine specifically, more encouraging in vitro results emerged in a paper published on March 9, in the journal Clinical Infectious Diseases. However, the data was not deemed sufficient by infectious disease experts to recommend the compound as a treatment yet, Medscape reported.
Christian Perronne, head of infectious diseases, University Hospital Raymond Poincaré, Garches, Paris, is enthusiastic about the potential of hydroxychloroquine to treat COVID-19. "I really believe in hydroxychloroquine. It is a drug I find rather fascinating, that has been used for decades," he told Medscape. "This could reduce the number of carriers, which I find interesting from an epidemiological perspective."
"I think from an ethical point of view, we should suggest it to all patients with severe disease who are hospitalized, under surveillance and on short treatment," he said. "Afterwards, in terms of adverse effects, at increased doses, it is possible that patients will have pain or fever, but it seems that the treatment is effective at lower doses, according to the Chinese data. In any case, the adverse effects of this compound are not dangerous."
Thomas Papo from Bichat Hospital, the University of Paris, noted that because the drug has been used for decades, we know lots about it.
"Hydroxychloroquine, vaunted by Didier Raoult as an anti-viral, has been used for decades in tens of thousands of patients, for several decades, so we have a huge follow-up and lots of data. This drug is remarkably well tolerated and we give it to all patients with lupus (for example), including in pregnant women. The main complication (retinal toxicity) is rare and does not last beyond 5 years of continuous use," he told Medscape.
Because the safety of hydroxychloroquine is well-established this should theoretically make it relatively easy to accelerate development into a treatment for COVID-19 if clinical trials are successful, especially given that it is cheap and not difficult to manufacture.
Scientists will continue to conduct trials of the substance in the immediate future. For example, Raoult's trial in Marseille is being extended.
Nevertheless, some experts such as Gilles Pialoux, an infectious disease specialist at Tenon Hospital, France, are more cautious over hydroxychloroquine, noting that there are potentially more promising treatments available, such as a drug called remdesivir.
Another potential antiviral treatment for COVID-19 known as Kaletrea—a combination of two drugs normally used to treat HIV, lopinavir and ritonavir—has turned out to be ineffective for the treatment of severe illness with SARS-CoV-2. According to a paper published in The New England Journal of Medicine, which involved 199 patients—99 of whom were given Kaletra—at a hospital in Wuhan, China, the treatment produced no observable benefit beyond standard care procedures [so why is this drug being discussed in this article?]. However, the researchers note that more research is needed to determine whether or not this treatment is effective against the virus. "Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit," the authors wrote in the study.
$AMRX
thanks for the info
Hudroxychloroquine google fda orange book and search for it. Or maybe this link will work: https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=A
Product Name:Hydroxychloroquine Sulfate, USP
Pronunciation:(hye drox ee KLOR oh kwin sul-fate)
Strength:200mg
Dosage Form:Tablets
Size:100
NDC:69238-1544-01
UPC:369238154412
OTC/Rx:RX
TE Code:AB
Reference Brand:Plaquenil®
Status:Active
Case Qty (min. order qty):24
Case Weight (lbs):3.92 lbs
Case Dimensions (LxWxH):12.375" x 8.375" x 4"
Pill Weight (mg):314mg
Pill Size:0.5" x 0.236" (CAPSULE SHAPED, CONCAVE ,PLAIN)
Bottle Size (LxWxH inches):1.7" x 1.7" x 3.3"
Bottle Weight (GM):60.95gm
Special Instructions:Keep this and all medication out of the reach of children. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Product Shelf Life:24 Months
Shape:Oblong
Color:White to off-white
Imprint/Markings:Debossed “AC54” on one side and plain on the other side
Note:See product insert for additional details including ingredients, dosage and administration.
$AMRX
they have hydroxychloroquine sulphate tablet, oral, ask sharky. Yeah i was thinking they would also should start ramping up, the key will be if announcement of it's effectiveness is proven gonna push through
Does any one have a clue if they manufacture chloroquine? It is not on their current product list. Do they have the ability to ramp up quickly? This company was linked to chloroquine in the past. Would love to hear any real insight
probably ramping up on production and any more great news on the effectiveness gonna go nicely
AMRX Outstanding Shares 147,109,015 as of 02/13/2020
$AMRX
yeah watching this one
52 week high 14.65
$AMRX
....just a hunch. Buy a little chunk. Imho.
AMRX
I was completely wrong!!
* * $AMRX Video Chart 12-16-2019 * *
Link to Video - click here to watch the technical chart video
* * $AMRX Video Chart 12-12-2019 * *
Link to Video - click here to watch the technical chart video
* * $AMRX Video Chart 12-03-2019 * *
Link to Video - click here to watch the technical chart video
* * $AMRX Video Chart 11-29-2019 * *
Link to Video - click here to watch the technical chart video
* * $AMRX Video Chart 11-06-19 * *
Link to Video - click here to watch the technical chart video
* * $AMRX Video Chart 10-25-2019 * *
Link to Video - click here to watch the technical chart video
* * $AMRX Video Chart 09-20-2019 * *
Link to Video - click here to watch the technical chart video
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
111
|
Created
|
01/16/19
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |